The global TAM for treatment of diabetes is massive. US equity markets have a lot of experience valuing continuous glucose monitoring (CGM) device makers such as the market leader, Dexcom (NYSE; DXCM);
- The global TAM for CGM device makers is c. US$5bn with cagr c.11%.
- DXCM current mkt value = US$35bn, equating to a revenue multiple of about x35!!!
- The point is, US equity markets go bananas over diabetes treatment innovation due to huge TAM, cagr and IP protection.
For the treatment of DFU's;
- TAM of US$7bn and likely c.10% cagr
- The application of Synpath to DFU's is a sleeping giant under the sp of PNV.
- Forums
- ASX - By Stock
- Ann: First Patient enrolled - SynPath Diabetic Foot Ulcer Trial
The global TAM for treatment of diabetes is massive. US equity...
Featured News
Add PNV (ASX) to my watchlist
|
|||||
Last
$2.36 |
Change
0.020(0.85%) |
Mkt cap ! $1.628B |
Open | High | Low | Value | Volume |
$2.33 | $2.40 | $2.33 | $1.160M | 491.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 5181 | $2.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.36 | 1873 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 8679 | 2.340 |
2 | 6803 | 2.330 |
4 | 9121 | 2.320 |
3 | 9362 | 2.310 |
12 | 25756 | 2.300 |
Price($) | Vol. | No. |
---|---|---|
2.370 | 10346 | 5 |
2.380 | 11247 | 3 |
2.390 | 6803 | 2 |
2.400 | 9791 | 4 |
2.410 | 12602 | 2 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |